Tuberculosis: Clinical trials and new drug regimens

Current Opinion in Pulmonary Medicine

Volumn 20, Issue 3, 2014, Pages 280-286

  Kwon, Yong Soo ^a   Jeong, Byeong Ho ^b   Koh, Won Jung ^b  

^a Chonnam National University Medical School   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

antitubercular agents; clinical trial; multidrug resistant tuberculosis; tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AZD 5847; BEDAQUILINE; BENZOTHIAZINONE DERIVATIVE; BTZ 043; CLAVULANIC ACID; CLOFAZIMINE; DELAMANID; GATIFLOXACIN; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NITROIMIDAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PROTIONAMIDE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAPENTINE; SUTEZOLID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; 2-(2-METHYL-1,4-DIOXA-8-AZASPIRO(4.5)DEC-8-YL)-8-NITRO-6-(TRIFLUOROMETHYL)-4H-1,3-BENZOTHIAZIN-4-ONE; 2-NITRO-6-(4-(TRIFLUOROMETHOXY)BENZYLOXY)-6,7-DIHYDRO-5H-IMIDAZO(2,1-B)(1,3)OXAZINE; ACETAMIDE DERIVATIVE; ADAMANTANE; ETHYLENEDIAMINE DERIVATIVE; N-GERANYL-N'-(2-ADAMANTYL)ETHANE-1,2-DIAMINE; OPC-67683; OXAZOLE DERIVATIVE; POSIZOLID; QUINOLINE DERIVATIVE; SPIRO COMPOUND; THIAZINE DERIVATIVE;

DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TUBERCULOSIS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); DRUG ADMINISTRATION; DRUG DESIGN; FEMALE; MALE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ACETAMIDES; ADAMANTANE; ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DIARYLQUINOLINES; DRUG ADMINISTRATION SCHEDULE; DRUG DESIGN; ETHYLENEDIAMINES; FEMALE; FLUOROQUINOLONES; HUMANS; LEVOFLOXACIN; MALE; NITROIMIDAZOLES; OXAZOLES; OXAZOLIDINONES; SPIRO COMPOUNDS; THIAZINES; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84897579469     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000045     Document Type: Review

References (67)

1. World Health Organization. Global tuberculosis report 2013. Geneva, Switzerland: World Health Organization; 2013.
2. Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013; 12:388-404.
3. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9:153-161.
4. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009; 4:e6914.
5. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients. PLoS Med 2012; 9:e1001300.
6. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42:156-168.
7. Rustomjee R, Lienhardt C, Kanyok T, et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12:128-138.
8. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009; 373:1183-1189.
9. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180:273-280.
10. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38:516-528.
11. International Union Against Tuberculosis and Lung Disease. Guidelines for clinical and operational management of drug-resistant tuberculosis. Paris, France: International Union Against Tuberculosis and Lung Disease; 2013.
12. Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47:653-657.
13. van den Boogaard J, Kibiki GS, Kisanga ER, et al. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009; 53:849-862.
14. Cremades R, Rodriguez JC, Garcia-Pachon E, et al. Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model. J Antimicrob Chemother 2011; 66:2281-2283.
15. Ahmad Z, Tyagi S, Minkowski A, et al. Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis. Am J Respir Crit Care Med 2013; 188:97-102.
16. Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10:605-612.
17. Peloquin CA, Hadad DJ, Molino LP, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52:852-857.
18. Koh WJ, Lee SH, Kang YA, et al. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2013; 188:858-864.
19. Migliori GB, Langendam MW, D'Ambrosio L, et al. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. Eur Respir J 2012; 40:814-822.
20. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drugsusceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002; 360:528-534.
21. Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353:1843-1847.
22. Dorman SE, Goldberg S, Stout JE, et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis 2012; 206:1030-1040.
23. Rosenthal IM, Zhang M, Williams KN, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007; 4:e344.
24. Mitchison DA. Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins. Int J Tuberc Lung Dis 2012; 16:1186-1189.
25. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365:2155-2166.
26. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012; 16:447-454.
27. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40:1430-1442.
28. Schecter GF, Scott C, True L, et al. Linezolid in the treatment of multidrugresistant tuberculosis. Clin Infect Dis 2010; 50:49-55.
29. Koh WJ, Kang YR, Jeon K, et al. Daily 300 mg dose of linezolid for multidrugresistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother 2012; 67:1503-1507.
30. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367:1508-1518.
31. Chang KC, Yew WW, Cheung SW, et al. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis? Antimicrob Agents Chemother 2013; 57:3445-3449.
32. Bolhuis MS, Altena RV, Soolingen DV, et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J 2013; 42:1614-1621.
33. Williams KN, Stover CK, Zhu T, et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 2009; 53:1314-1319.
34. Wallis RS, Jakubiec WM, Kumar V, et al. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J Infect Dis 2010; 202:745-751.
35. Wallis RS, Jakubiec W, Kumar V, et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother 2011; 55:567-574.
36. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307:223-227.
37. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360:2397-2405.
38. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: longterm outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56:3271-3276.
39. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. Geneva, Switzerland: World Health Organization; 2013.
40. Mase S, Chorba T, Lobue P, Castro K. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep 2013; 62:1-12.
41. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydroimidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006; 3:e466.
42. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2011; 15:949-954.
43. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrugresistant pulmonary tuberculosis. N Engl J Med 2012; 366:2151-2160.
44. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013; 41:1393-1400.
45. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380:986-993.
46. Dawson R, Diacon A. PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis. Expert Opin Investig Drugs 2013; 22:927-932.
47. Dey T, Brigden G, Cox H, et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2013; 68:284-293.
48. Gopal M, Padayatchi N, Metcalfe JZ, O'Donnell MR. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013; 17:1001-1007.
49. Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182:684-692.
50. Grosset JH, Tyagi S, Almeida DV, et al. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med 2013; 188:608-612.
51. Hugonnet JE, Tremblay LW, Boshoff HI, et al. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009; 323:1215-1218.
52. Gonzalo X, Drobniewski F. Is there a place for b-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. J Antimicrob Chemother 2013; 68:366-369.
53. Payen MC, De Wit S, Martin C, et al. Clinical use of the meropenemclavulanate combination for extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2012; 16:558-560.
54. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41:1386-1392.
55. Sacksteder KA, Protopopova M, Barry CE 3rd, et al. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol 2012; 7:823-837.
56. Reddy VM, Einck L, Andries K, Nacy CA. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother 2010; 54:2840-2846.
57. Reddy VM, Dubuisson T, Einck L, et al. SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro. J Antimicrob Chemother 2012; 67:1163-1166.
58. Makarov V, Manina G, Mikusova K, et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 2009; 324:801-804.
59. Pasca MR, Degiacomi G, Ribeiro AL, et al. Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones. Antimicrob Agents Chemother 2010; 54:1616-1618.
60. Lechartier B, Hartkoorn RC, Cole ST. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56:5790-5793.
61. Johnson JL, Hadad DJ, Dietze R, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 2009; 180:558-563.
62. Jawahar MS, Banurekha VV, Paramasivan CN, et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One 2013; 8:e67030.
63. Merle CS, Sismanidis C, Sow OB, et al. A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project. Trials 2012; 13:61.
64. Smythe W, Merle CS, Rustomjee R, et al. Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using Monte Carlo simulations. Antimicrob Agents Chemother 2013; 57:4164-4171.
65. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120:713-719.
66. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Organ 2001; 79:61-68.
67. Albanna AS, Smith BM, Cowan D, Menzies D. Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. Eur Respir J 2013; 42:721-732.